MetaCap

Emmis Acquisition (EMIS) vs Korro Bio (KRRO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Korro Bio (KRRO) has outperformed Emmis Acquisition (EMIS) over the past year, gaining 93.9% versus a gain of 4.4%. Korro Bio is the larger company by market cap ($167.2 million vs $163.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EMIS+4.39%KRRO+93.95%
+174%+74%-25%
Nov 21, 20251 yearNov 20, 2026
EMIS+4.60%KRRO-68.02%
+12%-39%-90%
Oct 20, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EMIS versus KRRO key metrics
MetricEMISKRRO
Share price$10.36$12.18
Market cap$163.36M$167.18M
1-day change+0.15%-0.08%
YTD return+4.07%+52.06%
1-year return+4.39%+93.95%
5-year return—-95.67%
EPS (TTM)—$-8.89
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$6.39M
Revenue growth (YoY)—+181.46%
Net income (latest FY)—$-117.26M
Operating margin—-1906.37%
Net margin—-1834.48%
52-week high$10.38$17.35
52-week low$9.92$5.20
Distance from 52-week high-0.24%-29.81%
Analyst consensus—strong_buy
Avg. price target upside—+76.52%
Average volume16.19K186.03K
Shares outstanding11.94M13.73M
Employees—58
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KRRO has outperformed EMIS by 89.6 percentage points over the past year.

About Emmis Acquisition

EMIS stock →

Emmis Acquisition Corp. focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.

Health Care · Biotechnology: Pharmaceutical Preparations

About Korro Bio

KRRO stock →

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees

EMIS vs KRRO FAQ

Which is bigger, Emmis Acquisition or Korro Bio?

Korro Bio (KRRO) is larger, with a market capitalization of $167.18M compared with $163.36M for Emmis Acquisition (EMIS).

Which stock has performed better over the past year, EMIS or KRRO?

KRRO returned +93.95% over the past 12 months, compared with +4.39% for EMIS (price return, excluding dividends). Past performance does not predict future results.

Are Emmis Acquisition and Korro Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons